UMBILICAL CORD TISSUE
Product Overview
-
Collection Methods
Following delivery, the cord is cut from the placenta and resected to procure tissue from the end of the cord. The cord is disinfected and placed in a sterile container for delivery to a processing laboratory. In the laboratory, the cord is diced to achieved cell selection and isolation.
-
Eligibility Determination
Donors are screened according to 21CFR 1271.75 using the questions found on the AABB uniform donor history questionnaire for cell therapy donors.
Additional questions can be added to a supplemental screening tool upon request.
-
Infectious Disease Testing
Testing is performed for all relevant communicable disease agents defined by the current edition of 21 CFR 610.40 and 21 CFR 1271.75.
All testing is done in compliance with 21 CFR 1271.80 and 21 CFR 1271.85. Only reagents that have been FDA cleared for donor screening are used. Results of testing on the screening date and the date of collection can be provided on the COA if requested.
-
A standard IRB approved consent is used to inform the donor of the risk and reward of the donation. The donor is fully aware that they can discontinue participation at anytime during the process.
-
Testing is performed for all relevant communicable disease agents defined by the current edition of 21 CFR 610.40 and 21 CFR 1271.75.
All testing is done in compliance with 21 CFR 1271.80 and 21 CFR 1271.85. Only reagents that have been FDA cleared for donor screening are used. Results of testing on the screening date and the date of collection can be provided on the COA if requested.
-
Sterility testing is performed on all units. The test method uses the Biomerieux BACT/ALERT system that complies with <USP> 71. Cultures are incubated for 14 days.
-
The 7AAD assay can be added to the flow cytometry enumeration marker to access the viability of specific cell populations.
-
All donor identifying information is confidential. While donor and product assessment data can be provided to a client, the identity of the donor is never provided. Non-Disclosure Agreements are initiated with all clients and their product and process information is not shared with any other entity or individual.
-
Quality systems have been established and include a quality plan, identification of critical control points (CCP), and key elements that provide process control for each CCP. Supplies, reagents, and equipment are verified against vendor claims and processes are validated using written IQ, OQ and PQ validation plans. SOPs are in place for each process step and all relevant data is documented concurrent with the performance of the task. Training programs for staff include documented assessments of understanding. Each element of 21CFR 211 and 21CFR 1271 are included in the quality system.